Pharmacotherapy used in psychiatry, particularly some antipsychotics (APs), may increase the risk of developing metabolic disorders. This creates a necessity for educating psychiatrists in the diagnosis, prevention, and treatment of these disorders in patients receiving APs. The aim of this article is to present the second part of the recommendations from the Polish Psychiatric Association (PTP) regarding the reduction of risk for obesity, diabetes, and metabolic disorders in people treated with APs, covering diagnosis and pharmacological treatment. The article complements part 1 of the recommendations, which is devoted to risk factors for the development of metabolic disorders and non-pharmacological interventions. Cardiometabolic risk assessment (including measurement of body weight, waist circumference, blood pressure, glycemia, glycated hemoglobin, and lipid profile evaluation) should be conducted before starting pharmacotherapy, and then again at 6 and 12 weeks of treatment, as well as every 12 months. In cases of weight gain, abnormalities in diagnostic tests, coexistence of metabolic risk factors, and when initiating treatment with APs that carry a high risk of metabolic disturbances (e.g., olanzapine, clozapine), consideration should be given to the introduction of metformin treatment at a dose of 1,000–2,000 mg/day, as the best-documented, safe, and inexpensive pharmacological method for preventing the development of metabolic disorders. Patients with obesity should be offered effective pharmacological treatment aligned with current guidelines. Through this treatment approach, psychiatrists can have a real impact on improving the metabolic health of their patients, reducing the risk of complications, and enhancing the quality of life of individuals with mental disorders.